Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Enliven TherapeuticsELVN | Open-market sale | 06/22 | 06/24 | 860,123 sh4 trades | $45.36avg. | $39,014,045.6 | −11.6% | |
Enliven TherapeuticsELVN | Open-market sale | 06/22 | 06/24 | 860,123 sh4 trades | $45.36avg. | $39,014,045.6 | −11.6% | |
Enliven TherapeuticsELVN | Open-market sale | 06/22 | 06/24 | 860,123 sh4 trades | $45.36avg. | $39,014,045.6 | −11.6% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 06/17 | 06/22 | 5,000 sh3 trades | $43.80avg. | $219,016.99 | −16.7% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 06/17 | 06/22 | 6,018 sh3 trades | $43.80avg. | $263,575.77 | −10.6% | |
Enliven TherapeuticsELVN | Open-market sale | 06/15 | 06/17 | 281,408 sh2 trades | $45.02avg. | $12,668,988.16 | −3.7% | |
Enliven TherapeuticsELVN | Open-market sale | 06/15 | 06/17 | 281,408 sh2 trades | $45.02avg. | $12,668,988.16 | −3.7% | |
Enliven TherapeuticsELVN | Open-market sale | 06/15 | 06/17 | 281,408 sh2 trades | $45.02avg. | $12,668,988.16 | −3.7% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 06/05 | 06/09 | 10,000 sh3 trades | $34.54avg. | $345,361.52 | −16.2% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 05/18 | 05/20 | 5,000 sh3 trades | $39.79avg. | $198,962.08 | −16.7% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 04/17 | 04/21 | 5,000 sh3 trades | $47.67avg. | $238,364.27 | −16.7% | |
Helen Louise CollinsChief Medical Officer | Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 03/25 | 03/27 | 40,000 sh | $35.10 | $1,404,000 | −61.5% |
Helen Louise CollinsChief Medical Officer | Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 03/17 | 03/19 | 5,000 sh | $27.76 | $138,800 | −16.7% |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 03/09–03/10 | 03/11 | 40,000 sh2 trades | $30.06avg. | $1,202,521.93 | −61.5% | |
Enliven TherapeuticsELVN | Open-market sale | 03/06 | 03/10 | 10,000 sh | $29.58 | $295,800 | −16.4% | |
Richard A. HeymanDirector | Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 02/17 | 02/19 | 1,230 sh | $26.18 | $32,201.4 | −5.2% |
Helen Louise CollinsChief Medical Officer | Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 02/17 | 02/19 | 45,000 sh | $26.17 | $1,177,650 | −64.3% |
Joseph P. LyssikatosChief Scientific Officer | Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 02/06 | 02/10 | 5,000 sh | $29.04 | $145,200 | −0.7% |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 01/20 | 01/22 | 1,230 sh2 trades | $26.75avg. | $32,904.8 | −4.9% | |
Enliven TherapeuticsELVN | Open-market sale10b5-1 plan | 01/20 | 01/22 | 20,000 sh2 trades | $26.75avg. | $535,089.77 | −2.6% |